Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million

The development could be a major, if costly, milestone for both the disease and the field of gene therapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.